CTLA4 and cancer: Although anti-CTLA-4 treatment has yielded encouraging outcomes in clinical trials in some forms of cancer, recent studies have demonstrated that it offers no clinical benefit in the context of OSCC, even when combining CTLA-4 inhibitors with other ICIs.